



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 23 Mar 2022 (#11)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022.** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
 - FMHS contact: cdevries@sun.ac.za
 - Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-137](#)

Type: R01

Application Due Date: 5 June 2022 through to 7 May 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA uses the R01 grant mechanism, whereas its companion FOA, [PAR-22-138](#), seeks shorter, higher-risk R21 grant applications.

Budget: Budgets for direct costs (excluding consortium F&A) of up to \$250,000 per year may be requested, for a maximum of \$1,250,000 direct costs (excluding consortium F&A) over a five-year project period.

2. Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-22-138](#) **Type:** R21

Application Due Date: 16 June 2022 through to 7 May 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org). This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity [PAR-22-137](#) seeks R01 grant applications.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

3. Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-22-139](#) **Type:** R01

Application Due Date: 5 June 2022 through to 5 February 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.

Budget: Application budgets are limited to not exceed \$500,000 per year in direct costs and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-22-140](#) **Type:** R21

Application Due Date: 16 June 2022 through to 16 February 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.

Budget: Application budgets are limited to not exceed \$275,000 in direct costs over two years and at most \$200,000 for any year. Budgets need to reflect the actual needs of the proposed project.

5. NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [PAR-22-141](#) **Type:** R21

Application Due Date: 16 June 2022 through to 7 May 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

Budget: The NEI permits direct costs up to \$275,000 for the entire two-year project period, plus applicable F&A for consortia. No more than \$200,000 in direct costs may be requested in any single year.

6. Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** [RFA-DA-23-004](#) **Type:** U01

Application Due Date: 11 August 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Drug Abuse (NIDA) seeks applications that support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine, methamphetamine, or cannabinoid use disorder

Budget: NIDA intends to commit \$5M in FY2023 to fund 1-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

7. Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-23-009](#)

Type: R21

Application Due Date: 15 August 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages exploratory and developmental research to better understand the role of social connectedness and/or loneliness in prevention, treatment and recovery from substance use disorders (SUDs). Research may use a variety of approaches, including leveraging existing data sources, survey research, social network analysis, new methods development, feasibility research, etc. Outcomes of interest include any of the following: substance use initiation, escalation, SUD diagnosis, connection to treatment, and engagement or retention in treatment or recovery.

Budget: NIDA intends to commit \$750,000 in FY 2023 to fund 3-4 awards. Direct costs are limited to \$275,000 over the 2-year project period, with no more than \$200,000 in direct costs allowed in any single year.

8. Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-23-010](#)

Type: R34

Application Due Date: 15 August 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials examining strategies to address social connectedness and/or loneliness in order to prevent or treat SUDs or enhance recovery. The goal of this FOA is to develop user-centered interventions addressing social connectedness and loneliness in the context of substance use that are effective, practical, cost-effective, scalable, and sustainable.

Budget: NIDA intends to commit \$750,000 in FY 2023 to fund 3-4 awards. Direct costs are limited to \$450,000 over the 3-year project period, with no more than \$225,000 in direct costs allowed in any single year.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105